226 related articles for article (PubMed ID: 32602003)
1. Landscape of RAS Variations in 17,993 Pan-cancer Patients Identified by Next-generation Sequencing.
Zhou S; Zhang D; Li J; Zhao J; Wang G; Zhang Y; Bai Y; Chen D; Wu H
Pathol Oncol Res; 2020 Oct; 26(4):2835-2837. PubMed ID: 32602003
[TBL] [Abstract][Full Text] [Related]
2. Landscape of
Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
[TBL] [Abstract][Full Text] [Related]
3. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
4. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
5. The Prevalence and Concurrent Pathogenic Mutations of
Liu Y; Li H; Zhu J; Zhang Y; Liu X; Li R; Zhang Q; Cheng Y
Cancer Manag Res; 2021; 13():2447-2454. PubMed ID: 33758543
[TBL] [Abstract][Full Text] [Related]
6. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
8. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.
Udar N; Lofton-Day C; Dong J; Vavrek D; Jung AS; Meier K; Iyer A; Slaughter R; Gutekunst K; Bach BA; Peeters M; Douillard JY
J Cancer Res Clin Oncol; 2018 Oct; 144(10):2001-2010. PubMed ID: 30019318
[TBL] [Abstract][Full Text] [Related]
9. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
10. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
11. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
13. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
14. The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer.
Costigan DC; Dong F
Genes Chromosomes Cancer; 2020 Mar; 59(3):152-159. PubMed ID: 31589789
[TBL] [Abstract][Full Text] [Related]
15. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
Ouerhani S; Elgaaied AB
Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
[TBL] [Abstract][Full Text] [Related]
16. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
[TBL] [Abstract][Full Text] [Related]
17. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
19. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U; Passiglia F; Cremolini C; Reale ML; Pepe F; Pisapia P; Avallone A; Cortinovis D; De Stefano A; Fassan M; Fontanini G; Galetta D; Lauricella C; Listì A; Loupakis F; Pagni F; Pietrantonio F; Pilotto S; Righi L; Bianchi AS; Parra HS; Tiseo M; Verzè M; Troncone G; Novello S
Eur J Cancer; 2021 Mar; 146():74-83. PubMed ID: 33588147
[TBL] [Abstract][Full Text] [Related]
20. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
